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Abstract
Interactions between cancer cells and cancer-associated fibroblasts (CAFs) play an important role in tumour
development and progression. In this study we investigated the functional role of CAFs in oesophageal
adenocarcinoma (EAC). We used immunochemistry to analyse a cohort of 183 EAC patients for CAF markers related
to disease mortality. We characterized CAFs and normal oesophageal fibroblasts (NOFs) using western blotting,
immunofluorescence and gel contraction. Transwell assays, 3D organotypic culture and xenograft models were used
to examine the effects on EAC cell function and to dissect molecular mechanisms regulating invasion. Most EACs
(93%) contained CAFs with a myofibroblastic (𝛂-SMA-positive) phenotype, which correlated significantly with
poor survival [p = 0.016; HR 7. 1 (1.7–29.4)]. Primary CAFs isolated from EACs have a contractile, myofibroblastic
phenotype and promote EAC cell invasion in vitro (Transwell assays, p ≤ 0.05; organotypic culture, p < 0.001)
and in vivo (p ≤ 0.05). In vitro, this pro-invasive effect is modulated through the matricellular protein periostin.
Periostin is secreted by CAFs and acts as a ligand for EAC cell integrins 𝛂v𝛃3 and 𝛂v𝛃5, promoting activation
of the PI3kinase–Akt pathway. In patient samples, periostin expression at the tumour cell–stromal interface
correlates with poor overall and disease-free survival. Our study highlights the importance of the tumour stroma in
EAC progression. Paracrine interaction between CAF-secreted periostin and EAC-expressed integrins results in PI3
kinase–Akt activation and increased tumour cell invasion. Most EACs contain a myofibroblastic CAF-rich stroma;
this may explain the aggressive, highly infiltrative nature of the disease, and suggests that stromal targeting may
produce therapeutic benefit in EAC patients.
© 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Oesophageal cancer is associated with extremely poor
overall survival; 60–70% of patients present with
late-stage disease, too advanced for treatment with
curative intent, and in those patients who are suitable
for multimodal therapy, 5 year survival is only 35%
[1]. This is partly due to the mechanically compli-
ant oesophageal anatomy, which allows symptomless
tumour expansion [2]. Additionally, tumour invasion
and metastasis are facilitated by the absence of an
outer serosal layer and the presence of a rich lymphatic
plexus. Depth of invasion and nodal metastasis are both
prognostic, and improving survival rates will require an
increased understanding of the molecular mechanisms
regulating local and regional tumour spread.
Although most cancer-related research has focused
on tumour cells [3–5], accumulating evidence suggests
that ‘normal’ cells within the tumour stroma (includ-
ing fibroblasts, endothelial and immune cells) play a
major role in tumour development and progression
[6]. Stromal features are prognostic in many tumour
types [7–11], and expression of stromal genes has
been shown to be associated with poor outcome in
oesophageal cancer [12].
Fibroblasts are probably the most abundant stromal
cells in most cancers, and are recognised to play a role
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in the development and progression of a range of epithe-
lial tumours [13]. Although fibroblasts within cancers
comprise a phenotypically heterogeneous population,
and the terminology is confusing [peritumour fibrob-
lasts, cancer-associated fibroblasts (CAFs), ‘activated’
fibroblasts], ‘activated’ CAFs are commonly described
as having a myofibroblastic phenotype; ie a secretory
and contractile cell which expresses α-smooth muscle
actin (α-SMA) [14,15]. These cells are responsible for
the stromal desmoplasia observed in a number of solid
cancers [16–18] and are associated with poor progno-
sis in several carcinoma types, including colorectal [10],
breast [19], ovarian [20] and head and neck cancers
[8]. CAFs regulate a number of tumour-promoting func-
tions, including invasion [21] and angiogenesis [22], and
may also affect tumour cell function by remodelling
and generating tissue tension [23]. CAFs are predom-
inantly derived from local fibroblasts, but it is clear
that other cell types, including stellate cells, pericytes
and circulating mesenchymal stem cells, can undergo
myofibroblast transdifferentiation [24]. Irrespective of
the progenitor cell, TGFβ1 signalling, in conjunction
with increased mechanical resistance of the extracellu-
lar matrix (ECM), is central to the transdifferentiation
process [25,26]. Notably, the stromal signature identi-
fied by Saadi and colleagues [12] in oesophageal cancer
patients contained a predominance of inflammation and
TGFβ-related genes.
To date, little is known regarding the role of the
tumour microenvironment, and in particular CAFs, in
the development and progression of EAC [27,28]. In this
study we investigated the prognostic and functional role
of CAFs in EAC and provide new insights into the role
of periostin in these processes.
Materials and methods
Tissue and cell collection, maintenance and RNAi
Tissue was collected and stored with ethical agreement
and informed consent; 09/H0504/66. Fibroblasts were
extracted from normal oesophagus and oesophageal ade-
nocarcinoma and subcultured as previously described
[29]. siRNA-mediated silencing of periostin was car-
ried out using INTERFERin transfection reagent and
two commercially available siRNA sequences (for full
details, see supplementary material, Supplementary
materials and methods).
Recombinant periostin
Periostin isoform 2 was subcloned and subsequently
purified from Hek293F cells (for full details, see sup-
plementary material, Supplementary materials and
methods).
Immunohistochemistry
Optimisation and staining of cohorts on full-face
sections, usingmousemonoclonal α-SMA (M085129-2,
Dako, USA) and polyclonal rabbit anti-periostin
(ab14041, Abcam, UK), was carried out on a Dako
Link automated staining machine, according to the
manufacturer’s instructions. Sections were scored by a
surgeon (TJU) and a pathologist (GT) blinded to patient
outcome, using the following protocol: negative, no
staining/<5%; moderate, patchy staining/5–50%; high,
> 50%, as previously described [8].
Western blotting
Cells (FLO-1 or primary fibroblasts) were treated under
different conditions including±fibroblast conditioned
medium,± recombinant periostin,±TGFβ1,±TGFβR1
kinase inhibitor IV (Calbiochem), ± LY294002 (Sigma)
and±αvβ3 and αvβ5 integrin antibodies (R&D Sys-
tems). Cells were treated with either TGFβ1 or inte-
grin receptor inhibitors for 1 h before treatment with
recombinant proteins (TGFβ1 and periostin) or clari-
fied conditioned medium (for full details of antibodies
used, experimental conditions and western blotting, see
supplementary material, Supplementary materials and
methods).
Immunofluorescence
Immunofluorescence analyses were carried out as
previously described [31]: primary antibodies, rabbit
polyclonal anti-periostin (ab14041, Abcam) and mouse
monoclonal anti-α-SMA (M085129.2, Dako); sec-
ondary antibodies, AlexaFluor 568 donkey anti-mouse
IgG and AlexaFluor 488 goat anti-rabbit IgG (Molecular
Probes).
Organotypic cultures
Organotypic cultures were carried out as previously
described [29,32]. NOFs or CAFs were co-cultured with
either OE33 or FLO-1 cells for 14 days. Fibroblasts were
pretreated with POSTN siRNA sequence 1 (Ambion)
before embedding in organotypic cultures, and matured
for 10 days. Organotypics treated with 10 μM LY294002
were matured for 14 days. Invasion was quantified and
compared as previously described [33].
Transwell invasion
Transwell invasion assays were carried out as previ-
ously described [32]: 24 h-conditioned medium from
NOFs or CAFs (plated in identical numbers)±POSTN
siRNA pre-treatment, ± TGFβ1 pre-treatment. Addi-
tion of 5 μg/ml recombinant POSTN was used as the
chemoattractant in the bottom chamber where indi-
cated. Blocking antibodies for αvβ3 and αvβ5 integrins
(10 μg/ml; R&DSystems) and PI3K inhibitor LY294002
(10 μM; Sigma) were added to the top chamber in com-
bination with FLO-1 or OE33 cells for the duration of
the experiment (72 h). All experiments were repeated
three times, with four replicates/experiment. Normal-
isation was performed to the mean value of replicate
1 for all experimental conditions and data expressed as
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percentage invasion compared to the appropriate control
(ie negative control siRNA- or vehicle-treated cells).
Gel contraction
Gel contraction assays were carried out as previously
described [8]: 0.5× 106 normal or CAFs (±POSTN
siRNA knockdown) were seeded in collagen-1 gels.
Tumour xenografts
OE33 or OANC1 cells (5× 106)±NOFs or CAFs
(1× 106) were injected subcutaneously into the flanks
of SCID mice (one injection/mouse) in a 1:1 mixture of
PBS and Matrigel™ (BD Biosciences; for full details of
this model, see supplementary material, Supplementary
materials and methods).
Data acquisition and processing for network
analysis
Weighted gene correlation network analysis (WGCNA)
[34,35] was applied to microarray datasets generated on
Affymetrix HG-U133A GeneChips from two indepen-
dent studies (for full details of this analysis, see supple-
mentary material, Supplementary materials and meth-
ods).
Statistical analysis
Statistical analysis was performed with SPSS® v 19
(SPSS, Chicago, IL, USA). Survival of patients was
plotted using the Kaplan–Meier method and analysed
using the log-rank test, with patients censored at last
follow-up.Multivariate Cox logistic regression was used
to assess the relationship between α-SMA and standard
pathological variables after resection. Kruskal–Wallis
andMann–Whitney U- and t-tests were used to compare
groups, as appropriate; p< 0.05 was considered statisti-
cally significant for all tests (*p< 0.05, **p< 0.01).
Results
High α-SMA expression is common in EAC
and correlates with poor overall survival following
oesophageal resection
We used immunochemistry to examine the expres-
sion of α-SMA in the stroma of tumours from 183
patients following oesophageal resection (median
follow-up= 4.5 years; 81 cancer-related deaths). Mod-
erate/high expression of α-SMA (α-SMA-positive)
was found in the majority of cases (n= 171). In 12
cases an α-SMA-negative stroma was observed, and
this group of patients had a significant overall survival
advantage [Figure 1A; mean survival α-SMA nega-
tive= 78.66months (median not yet reached) versus
α-SMA-positive= 48.14months; p= 0.016 (median 39
months; 95% CI 29.2–48.8)]. The α-SMA-negative
group was further analysed to exclude the possibility
that it was biased towards early-stage disease; this
was not the case. The pathological stages according
to the AJCC (7th edn) classification of EAC [36] for
the patients in this group were: stage 0, one patient;
stage IA, three patients; stage IIA, one patient; stage
IIB, two patients; stage IIIA, two patients; stage IIIB,
one patient; and stage IIIC, two patients. When α-SMA
expression was compared against other commonly
used indicators of prognosis following surgery (TNM
stage [36,37] and resection clearance: R status) in a
Cox regression model, α-SMA expression was the
most predictive factor analysed: hazard ratio (HR)
7.1 (1.7–29.4); p= 0.007 (Table 1). Full details of
the patient demographics are shown in Table S1 (see
supplementary material).
Ex vivo analysis of primary oesophageal CAFs
reveals a myofibroblast phenotype that can be
induced by TGFβ
CAFs were cultured directly from tumour tissue and
NOFs from macroscopically and microscopically
normal areas of mucosa at the proximal resection
margin. NOFs and CAFs were characterised using
cell-type specific markers, confirming a fibroblastic
phenotype [vimentin-positive, cytokeratin-negative,
CD31-negative (Figure 1B; see also supplementary
material, Figure S1A) and desmin-negative (data not
shown)]. CAFs expressed high levels of α-SMA, con-
firming a myofibroblast phenotype (Figure 1B). In
an additional panel of primary fibroblasts, seven of
eight CAFs expressed high levels of α-SMA com-
pared with low or absent α-SMA levels in NOFs, in
keeping with the immunohistochemical analysis of
paraffin-embedded tissues (see supplementary mate-
rial, Figure S1B). α-SMA stress fibre formation was
observed in CAFs but not NOFs (Figure 1C). In gel
contraction assays there was a significant reduction in
gel size and weight in the presence of CAFs compared
to NOFs (weight, p< 0.01), demonstrating the ability
of CAFs to contract an in vitro ECM (Figure 1D).
Gene ontology analysis of the stromal signature in the
progression of pre-invasive to invasive disease in EAC
has previously identified TGFβ signalling as a critical
pathway in this transition [12]. Treatment of NOFs with
TGFβ1 for 72 h resulted in high levels of α-SMA expres-
sion, stress fibre formation and increased gel contraction
(gel weight NOFs 0.21 g versus NOFs+TGFβ1 0.15 g;
p< 0.01), confirming myofibroblast transdifferentiation
(Figure 1E). In addition, exposure of NOFs to condi-
tioned medium from FLO-1 cells for 72 h resulted in a
TGFβ1-dependent up-regulation of α-SMA (see supple-
mentary material, Figure S1C).
CAFs promote EAC cell invasion in vitro
To determine whether CAFs secrete factors that pro-
mote EAC cell invasion, Transwell invasion assays
were performed using EAC cell lines FLO-1 and OE33.
Conditioned medium from NOFs or CAFs was used as a
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Figure 1. CAFs in the microenvironment are important in EAC. (A) Kaplan–Meier curve of overall survival after resection in patients with
α-SMA-positive versus α-SMA-negative tumours; representative IHC images of negative/low and positive/high are in the right-hand panel.
(B) Western blot for pan-cytokeratin and vimentin in FLO-1, OE33 and primary oesophageal NOFs and CAFs. (C) Immunocytochemistry for
α-SMA in primary oesophageal NOFs and CAFs. (D) Photograph of a representative gel contraction assay at 72 h and gel weight with the
incorporation of CAFs compared to NOFs (p< 0.01; n= 3). (E) Western blot and immunocytochemistry for α-SMA in NOFs and NOFs+ TGFβ1,
and a representative gel contraction assay
chemoattractant in the lower chamber of the Transwell.
CAFs-conditioned medium promoted a> two-fold
increase in invasion of both EAC cell lines (p< 0.05;
Figure 2A). The proliferation of FLO-1 cells exposed to
either NOF- or CAF-conditioned medium was assessed
by MTS assay, and no difference was observed (see sup-
plementary material, Figure S2B). Using organotypic
cultures as a more physiologically relevant model of
tumour cell invasion [29], we further explored the role
of EAC CAFs in this process. Invasion in these models
was quantified and compared, taking into account the
average depth of tumour invasion and the number and
area of invading tumour islands [33]. Minimal invasion
was seen in NOFs-containing gels, but in the presence
of CAFs, EAC cell invasion was significantly increased
for both tumour cell lines [mean total area of invasion,
arbitrary units (n= 3), FLO-1+NOFs 2670.3 versus
FLO-1+CAFs 3862.3; p< 0.001: OE33+NOFs 501
versus OE33+CAFs 6238.3; p< 0.001: Figure 2B; see
also supplementary material, Figure S2A].
CAFs promote tumour growth in vivo
The ability of CAFs to support tumour growth in
vivo was assessed using a xenograft model. The cell
line FLO-1 was non-tumourigenic in this model and
therefore experiments were performed using OE33
cells. Xenografts from OE33 cells injected subcuta-
neously, either alone (n= 15) or mixed with NOFs
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Table 1. Cox regression analysis of α-SMA expression compared
against other commonly used indicators of prognosis following
oesophageal resection for EAC
95% Confidence interval
Pathological
variable
Hazard
ratio Lower Upper
Significance
(p)
pT stage
1.49 1.14 1⋅95 0.003
pN stage 1.78 1.45 2⋅18 < 0.001
pM stage 1.57 0.62 3⋅96 0.343
Positive resection
margin (R1)
1.31 0.81 2⋅11 0.271
α-SMA-positive
stroma
7.07 1.70 29⋅39 0.007
(n= 9) or CAFs (n= 9), did not grow uniformly and
therefore the mice were culled when the tumour
volume had reached 500mm3, and groups were com-
pared by Kaplan–Meier analysis. Mice receiving
co-injections of OE33 cells and CAFs were culled sig-
nificantly earlier (median survival OE33+CAFs= 100
days versus OE33+NOFs= 163.5 days; p= 0.04;
Figure 2C). Immunostaining for α-SMA confirmed
the retained presence of CAFs in these tumours sur-
rounding cytokeratin-positive tumour cells (Figure 2D).
Mice injected subcutaneously with an additional
EAC cell line, OANC1+CAFs (n= 4), developed
tumours that grew more rapidly than those injected with
OANC1+NOFs (n= 4) (see supplementary material,
Figure S2C).
Periostin is secreted by CAFs and promotes tumour
cell invasion
Saadi and colleagues [12] recently described a stromal
gene expression signature that is predictive of outcome
in EAC. To complement this differential expression
study, we applied WGCNA [38] to a publicly avail-
able EAC microarray dataset [39]. Seven modules of
highly co-expressed genes were identified by unsuper-
vised hierarchical clustering on the basis of topologi-
cal overlap (TO) and labelled by colour (Table 2). The
co-expression network was strongly preserved in an
independent dataset [40].
ToppGene analysis indicated that the pinkmodulewas
highly enriched for genes associated with fibroblasts
(GSM777043; Bonferroni adjusted p= 3.1× 10−83).
Concomitant with this finding, the top Gene Ontology
(GO) category for the pink module was ‘extracellular
matrix organisation’ (Table 2); among the enriched
Figure 2. CAFs promote EAC cell invasion in vitro and tumour growth in vivo. (A) Transwell invasion assays comparing the effect of NOFs
and CAFs conditioned medium on invasion of the EAC cell lines FLO-1 and OE33. (B) Organotypic models of EAC comparing the effect of
NOFs and CAFs to promote invasion of FLO-1 and OE33. (C) Kaplan–Meier curves of overall survival of mice injected with OE33 alone or in
combination with NOFs or CAFs. Mice were culled when the tumour volume reached 500mm3. (D) Immunohistochemistry for Pan-CK and
α-SMA in tumour xenografts containing OE33 and CAFs
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Table 2. Correlation matrix of seven modules (labelled by colour) of highly co-expressed genes that have been identified by unsupervised
hierarchical clustering on the basis of topological overlap
Module colour Number of genes Module preservation (Zsummary) Module Gene Ontology Bonferoni (p)
Black 788 10 Intracellular transport 5.20E-11
Blue 1143 50 Skin development 1.10E-17
Brown 384 16 Cell cycle process 7.20E-06
Cyan 271 29 Nucleotide metabolic process 6.50E-06
Grey 745 13 DNA metabolic process 4.50E-15
Light green 467 39 Antigen processing and presentation 1.20E-06
Pink 202 23 Extracellular matrix organization 2.70E-34
The Zsummary is a composite statistic of density and connectivity preservation for the module: < 2, no preservation; 2–10, weak to moderate preservation; > 10,
strong evidence of preservation.
genes were α-SMA, fibrillin 1 and periostin. Unsuper-
vised hierarchical clustering of the ECM module genes
differentiated between normal oesophageal epithelium
and EAC (Figure 3A). These observations are consistent
with the ECM module representing genes expressed by
a CAFs-rich stroma.
The relative importance of each gene within its
respective module can be estimated by a module mem-
bership measure (KME) [38]. Periostin had a high KME
value (0.87), denoting centrality and importance within
the ECM module; a full list of KME values is provided
in Table S2 (see supplementary material). Of the top 86
nearest neighbours of periostin (TO threshold≥ 0.15;
Figure 3B), 52 of the genes were annotated for the GO
categories ECM organization (adjP= 4.1× 10−27), bio-
logical adhesion (adjP= 7.0× 10−17) and locomotion
(adjP= 3.2× 10−8).
We therefore examined whether the tumour-
promoting effects of CAFs are modulated through
periostin. Conditioned medium from CAFs contained
higher levels of periostin compared to NOFs by
western blot and immunocytochemistry (Figure 3C).
siRNA-silencing of POSTN in CAFs suppressed
periostin expression and resulted in a> 50% sup-
pression of tumour cell invasion in Transwell assays
(p< 0.05; Figure 3D). POSTN silencing in CAFs also
resulted in complete loss of invasion by EAC cells in
organotypic culture (mean total area of invasion, arbi-
trary units; n= 3; control siRNA 1187.7 versus POSTN
siRNA 3581; p< 0.001; Figure 3E). To further confirm
that the inhibition of tumour cell invasion was directly
modulated through reduced periostin expression, we
immunodepleted periostin from CAFs-conditioned
medium and observed a similar reduction in invasion
(p< 0.05). This was restored by addition of recombi-
nant periostin (Figure 3 F). Fibroblast proliferation after
periostin silencing was not significantly different to
control siRNA-treated cells (data not shown).
We had previously found that TGFβ1 treatment
of NOFs generated a myofibroblastic phenotype
(Figure 1D, E). TGFβ1-treated NOFs also up-regulated
POSTN (Figure 3G) and promoted EAC invasion
(p< 0.01). Periostin silencing did not affect the
up-regulation of α-SMA in TGFβ1-treated NOFs (see
supplementary material, Figure S3F). The increase in
EAC invasion was again periostin-dependent and abro-
gated by POSTN down-regulation. Furthermore, the
addition of recombinant periostin to NOF-conditioned
medium significantly increased EAC cell inva-
sion in Transwell assays to levels comparable to
CAF-conditioned medium (Figure 3H).
Periostin treatment of EAC cells results in integrin-
and PI3K-dependent activation of Akt
We examined potential periostin-dependent downstream
signalling pathways in EAC cells and found Akt to be
consistently phosphorylated following periostin treat-
ment. PI3K–Akt signalling has been reported to be
a critical regulator of cell motility in several cancer
types, including EAC, and we explored this response
in more detail. Recombinant periostin was added to
tumour cells and phosphorylation of Akt was observed
at 30min post-stimulation, which persisted for at least
120min (Figure 4A). Periostin is a ligand for several
integrins, including αvβ3 and αvβ5, and so we exam-
ined whether periostin-dependent Akt activation is mod-
ulated through integrin binding. After confirming the
presence of αvβ3 and αvβ5 on the surface of EAC cells
by western blot and flow cytometry (see supplemen-
tary material, Figure S3A, B), we found that phospho-
rylation of Akt in response to periostin was suppressed
by blocking antibodies directed against αvβ3 or αvβ5
(Figure 4B). The suppression of Akt phosphorylation
in periostin-treated cells, in the presence of the PI3K
inhibitor LY294002 confirmed that Akt phosphorylation
was PI3K-dependent (Figure 4C). Similar effects on Akt
activation were observed in FLO-1 cells after 30min
treatment with CAFs-conditioned medium (see supple-
mentary material, Figure S3E).
Periostin-dependent invasion is suppressed through
inhibition of αvβ3, αvβ5 and PI3K
We repeated Transwell invasion assays to examine the
effect of inhibiting αvβ3/αvβ5–PI3K–Akt signalling
in EAC cells. NOF-conditioned medium supplemented
with recombinant POSTN or CAF-conditioned medium
promoted EAC invasion (>3.5-fold; Figure 4D) and this
was inhibited by the addition of αvβ3- or αvβ5-blocking
antibodies, or a PI3K inhibitor, LY294002, to the
tumour cells. Invasion of EAC cells in organotypic
culture containing CAFs was significantly reduced in
the presence of LY294002 (mean total area of inva-
sion, arbitrary units (n= 3), FLO-1+CAFs 11961
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Figure 3. Periostin is secreted by CAFs and promotes EAC cell invasion. (A) Unsupervised hierarchical clustering of the ECM module
genes differentiated between normal oesophageal epithelium and EAC. (B) Exported network weights in BioLayout Express3D, graphically
representing periostin as a central gene within the ECM module, with many connections to other ECM module genes and genes associated
with the cell-cycle process. (C) Western blot of conditioned medium and immunocytochemistry, comparing the expression and secretion
of periostin in NOFs and CAFs. (D) Transwell invasion assays, demonstrating the invasion of FLO-1 in response to CAF-conditioned
medium± periostin silencing, as indicated (*p< 0.05; **p< 0.001), with western blot of conditioned medium normalized to cell number
confirming periostin knockdown. (E) Organotypic cultures of FLO-1 and CAFs, with and without periostin silencing. (F) Transwell invasion
assays of FLO-1 towards CAF-conditioned medium, with or without periostin immunodepletion and rescue with recombinant periostin, as
indicated (*p< 0.05). (G) Transwell invasion assay of FLO-1 towards conditioned medium from NOFs or NOFs+ TGFβ1, with and without
periostin silencing, and western blot analysis of periostin expression under the same conditions (**p< 0.001). (H) Transwell invasion assay
of FLO-1 towards conditioned medium from NOFs± recombinant periostin or CAFs, as indicated (**p< 0.001)
versus FLO-1+CAFs+LY294002 338.7; p< 0.001;
Figure 4E). Proliferation of FLO-1 cells was not
affected by treatment with LY294002 in organotypic
assays, shown by Ki67 staining (Figure 4E), percentage
of Ki67-positive cells in 10 high-power fields (vehi-
cle= 87± 5, LY294002= 89± 3). This was confirmed
by MTS assays across a range of concentrations (see
supplementary material, Figure S3C). An increase
in caspase-8 expression (not cleavage) was observed
(see supplementary material, Figure S3D). To confirm
Akt activation in human EAC tumours, we performed
immunohistochemistry (IHC) and observed pAkt in
tumour cells, with the strongest staining adjacent to
CAFs (Figure 4 F). High stromal periostin expression
was observed in the mouse xenograft model containing
OE33 and CAFs, and activation of Akt was confirmed
in this model by high pAkt staining in adjacent tumour
cells (Figure 4G).
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Figure 4. Periostin-dependent invasion of EAC cells is suppressed through inhibition of αvβ3 and αvβ5 integrins and PI3K. (A) Western blot
for total and phospho-Akt in FLO-1 up to 120min after stimulation with recombinant periostin. (B) Western blot for total and phospho-Akt
in FLO-1, 30min after periostin stimulation, in the presence or absence of blocking antibodies against integrins αvβ3 or αvβ5, as indicated.
(C) Western blot for total and phospho-Akt in FLO-1, 30min after periostin stimulation, in the presence or absence of the PI3K inhibitor
LY294002. (D) Transwell invasion assays of FLO-1 towards NOFs or CAFs conditioned medium under varying conditions. Invasion towards
NOF-conditioned medium is used as the internal control. Periostin was added to the NOF-conditioned medium and either LY294002 or
blocking antibodies against integrins αvβ3 or αvβ5 were added to the FLO-1 cells, as indicated. (E) Organotypic models of FLO-1+ CAFs
in the presence or absence of LY294002, including staining by H&E, pan-cytokeratin and Ki67. (F) Immunohistochemistry for p-Akt in
representative human EAC tumours with strongest staining adjacent to CAFs. (G) Immunohistochemistry for periostin and p-Akt in tumour
xenografts containing OE33 and CAFs
Periostin expression predicts survival after resection
for EAC
Having established the importance of periostin to
CAFs-induced EAC cell invasion in vitro, we examined
our EAC patient cohort to confirm the presence of
stromal periostin by IHC. Similar to α-SMA expression,
moderate/high expression of periostin was observed in
the majority of cases (n= 166; periostin-positive), with
periostin localised to the cancer cell–stromal interface
(Figure 5C, D), corresponding to areas of high α-SMA
expression (Figure 5D) in keeping with a myofibrob-
lastic CAFs origin. Periostin expression was limited
to blood vessel walls in normal oesophageal mucosa
(Figure 5C).
In 17 cases there was no/minimal periostin staining
(periostin-negative) and this group of patients had a
significant overall survival advantage when compared
with periostin-positive patients [Figure 5A; mean sur-
vival periostin-negative= 76.45months (median not yet
reached) versus periostin moderate/high= 46.80months
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Figure 5. Stromal periostin expression correlates with poor survival in EAC. (A) Kaplan–Meier curves of overall survival after resection
in patients with periostin-positive versus periostin-negative tumours. (B) Kaplan–Meier curves of disease-free survival after resection in
patients with periostin-positive versus periostin-negative tumours. (C) Immunohistochemistry for periostin expression in human normal
oesophagus (limited to the walls of blood vessels) and EAC. (D) Immunohistochemistry to compare expression patterns of periostin and
α-SMA in EAC
(median 39 months); p= 0.009]. We also examined the
effect of periostin expression on disease-free survival
(Figure 5B). Patients with no periostin staining in their
resected tumours had a mean time to recurrence of
80.67months (median not yet reached). Patients with
high levels of periostin staining in the resected tumours
experienced the shortest mean time to recurrence of
47.45months (median 38 months; p= 0.006).
Discussion
The traditional model of EAC development describes
progressive cellular dysplasia and accumula-
tion of mutations in response to persistent acid
reflux and inflammation [41]. Whole-genome and
exome-sequencing studies are beginning to define the
complexity of EAC, but suggest that the mutational
burden may already be established in non-dysplastic BE
[42–44], meaning that the drivers for disease progres-
sion lie beyond gene mutations in the epithelial cells
and that the stromal tissues play a critical role in disease
development and progression.
However, very little is known about the role of the
tumour microenvironment/stroma in oesophageal can-
cer [27,28]. CAFs are a heterogeneous cell type, and
no single marker reliably identifies all CAFs. They
are most commonly identified by α-SMA expression,
indicative of an ’activated’ myofibroblast-like pheno-
type. We found that the vast majority of patients with
EAC have tumours with high or moderate levels of
stromal α-SMA; this predicts poor survival and may
account, in part, for the aggressive nature of the disease.
Retrospective studies have intrinsic limitations and the
uneven distribution of SMA expression in our cohort
raises the possibility of a type 1 error; however, this
may reflect the importance of the CAFs phenotype in
EAC, which is clearly supported by the in vitro and in
vivo data. EAC CAFs cultured from primary tumours
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have an α-SMA-positive, contractile, myofibroblastic
phenotype; they express a range of mesenchymal and
fibroblast-specific markers, and promote EAC invasion
in vitro and tumour growth in vivo. We provide evi-
dence of a potential mechanism by showing that the
invasion-promoting effect of CAFs is modulated, in part,
through periostin, a secreted matricellular protein that
plays an important role in tissue remodelling and colla-
gen fibrillogenesis, interacting with ECM proteins such
as fibronectin, tenascin C and collagen V, and with
cell surface receptors, most notably integrins, includ-
ing αvβ3, αvβ5 and α6β4 [45–47]. We found that CAFs
express high periostin levels in vitro and in vivo, and acti-
vate tumour cell PI3K–Akt signalling through integrin
binding. Similar to α-SMA, periostin expression also
predicts poor outcome in EAC patients.
A stromal gene-expression signature containing
periostin has previously been shown to predict out-
come in EAC [12]. However, most cancer studies
have found periostin to be of tumour cell origin, with
over-expression documented in a range of tumours,
including lung, breast, ovary and pancreas [48]. Its
functional role in cancer is not clear, although expres-
sion correlates with poor outcome in several cancers,
suggesting a tumour-promoting effect, and, consistent
with this, periostin has been reported to modulate a
number of the hallmarks of malignancy [48]. Metas-
tasising breast cancer cells induce periostin secretion
in the cancer stem cell niche and require continued
stromal periostin expression for cancer stem cell main-
tenance [49]. Importantly, disruption of the interaction
between periostin and the integrin receptors αvβ3 and
αvβ5 by periostin-binding DNA aptamers blocked
signal transduction and reduced primary tumour growth
and metastasis in an orthotopic breast cancer mouse
model [50], suggesting that targeting periostin has
therapeutic potential. Periostin is involved in remod-
elling of the ECM to support tumour development,
invasion and metastasis [48]. Periostin has also been
identified as a key component of an invasive signature
in a three-dimensional (3D) organotypic model of
oesophageal squamous cell carcinoma [51]. We have
confirmed the importance of periostin in EAC biology.
Applying WGCNA to publicly available EAC microar-
ray datasets has identified periostin to have a ’nodal’
position within ECM gene expression in EAC, with
close associations with genes involved in cancer cell
invasion, adhesion and locomotion.
Periostin contains a FAS1 domain that allows binding
of αv-integrins and glycosaminoglycans in vivo. Inter-
action with these cellular receptors can lead to diverse
downstream signalling effects in a context-dependent
manner (NF-κB, STAT3, PI3K–Akt and FAK), con-
trolling the expression of many genes (including
α-SMA, collagen and fibronectin) [52]. We found that
periostin treatment of EAC cells results in integrin- and
PI3K-dependent activation of Akt, and furthermore that
periostin-dependent EAC cell invasion is suppressed
through inhibition of αvβ3, αvβ5 and PI3K. These
findings suggest not only that periostin is very likely to
be important for EAC cell invasion in vivo, but also that
this is mediated by integrin–PI3K–Akt signalling. The
PI3K signalling pathway integrates intra- and extracel-
lular signals to modulate a multitude of downstream
responses, effected by multiple substrates [53]. PI3K
activation in response to integrin signalling is well doc-
umented in cancer, and there are some reports of Akt
activation leading to tumour cell invasion in response
to integrin-mediated periostin signalling in epithe-
lial tumours, eg integrin α5β1 in cholangiocarcinoma
[47]. Canonical PI3K–Akt signalling is frequently
dysregulated in cancer and can determine cell growth,
proliferation, angiogenesis, migration and invasion [54].
The fact that periostin has been implicated in many of
the same processes suggests that the PI3K–Akt pathway
may act as a node for periostin signalling in cancer. Our
findings suggest that in EAC it may be possible to target
periostin–intergrin–PI3K–Akt signalling at multiple
levels with new and existing therapeutics. Further work
is needed to confirm this hypothesis. For instance, it will
be important to know whether periostin is prognostic in
pretreatment biopsies from EAC, and whether or not the
presence of periostin predicts response to neoadjuvant
chemotherapy.
In conclusion, our study highlights the importance
of the tumour stroma in EAC progression. The major-
ity of EACs contain a prominent myofibroblastic
(α-SMA-positive) CAFs-rich microenvironment, and
stromal α-SMA expression is more significantly prog-
nostic than conventional histopathological criteria.
CAFs isolated from EAC have a functional myofibrob-
lastic phenotype, and promote tumour cell invasion in
vitro and growth in vivo, signalling to EAC cells via
secretion of the ECM protein, periostin. Disruption
of periostin signalling via integrin receptors and the
PI3K–Akt pathway leads to abrogation of cancer cell
invasion. This opens the possibility of targeting CAFs
and their paracrine signals as treatment strategies in
oesophageal cancer.
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